HPV Transcriptome as a Game-Changing Biomarker for Detection, Genotyping, and Monitoring of HPV-Associated Cervical High-Grade Cytology
LUXEMBOURG, LUXEMBOURG, April 22, 2025 /EINPresswire.com/ — Advanced Biological Laboratories (ABL), a diagnostics company, headquartered in Luxembourg, is pleased to announce a licensing agreement with the renowned Institut Pasteur for the integration of the innovative HPV RNA-Seq technology into its diagnostic solutions.
HPV RNA-Seq is a cutting-edge diagnostic method that enhances the detection and typing of high-risk human papillomavirus (HPV) infections. This technology not only identifies the presence of HPV but also determines the specific viral strains and assesses the risk of progression to cervical cancer. HPV RNA-Seq demonstrated superior sensitivity compared to traditional DNA-based tests, detecting additional HPV-positive cases and multiple infections that were previously unrecognized (https://doi.org/10.1016/j.jmoldx.2019.04.010).
Furthermore, HPV RNA-Seq technology is already capable of competing with cytology tests, providing a highly sensitive and precise alternative for HPV monitoring. Its advanced capabilities make it a true game changer, as it has the potential to ultimately replace HPV screening tests altogether. By offering a more reliable method for early detection and risk assessment, this technology revolutionizes current strategies for monitoring HPV patients and significantly enhances patient care.
By incorporating HPV RNA-Seq into its product portfolio, ABL aims to provide healthcare professionals with more precise and comprehensive tools for early detection and management of HPV-related conditions. This advancement aligns with the company’s commitment to enhancing patient outcomes through innovative diagnostic solutions.
“We are excited to collaborate with the Institut Pasteur to bring this state-of-the-art technology to clinicians worldwide,” said Dr. Chalom Sayada, CEO of ABL. “This agreement underscores our dedication to advancing molecular diagnostics and improving the accuracy of HPV screening. HPV RNA-Seq is a disruptive innovation that is set to redefine how HPV infections are diagnosed and managed.”
“We worked for several years to develop the HPV RNA seq technology at the Institut Pasteur, together with Prof. Marc Eloit, inventor of the technology. Support from the Institut Pasteur Innovation Accelerator and guidance from the Technology Transfer and Industrial Partnership Department (DARRI) were decisive in achieving a sufficient TRL and envisaging an industrial transfer. The signature of the license with ABL marks an important milestone in the project. We are convinced that this collaboration will enable us to put this innovation at the service of clinicians and patients, thus contributing to the prevention of cervical cancer”, added Philippe Pérot, co-inventor of the HPV RNA-Seq technology and Expert Research Engineer at the Institut Pasteur.
The global market for HPV testing and related disease monitoring is experiencing significant growth, driven by the increasing prevalence of cervical cancer and heightened awareness of early detection methods. In 2022, the market was valued at approximately USD 3.90 billion and is projected to grow at a compound annual growth rate (CAGR) of 11.8%, reaching an estimated USD 9.33 billion by 2030. (GrandViewResearch, Report ID: 978-1-68038-895-4).
This robust growth underscores the escalating demand for advanced diagnostic tools in HPV detection and genotyping. With the introduction of HPV RNA-Seq, ABL is at the forefront of a transformation in HPV diagnostics, providing a superior alternative to traditional screening methods and paving the way for more effective disease prevention strategies.
The financial terms of the agreement remain undisclosed.
***